Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
for Hormone Receptor-positive Breast Cancer
7 locations incl. New Haven
Sponsor: Ellipses Pharma
Sex: Female·Age: 18+
Code: NCT05573126·Phase 1, Phase 2·Recruiting